The results of a phase 1/2 clinical trial in Europe of an investigational Lyme disease vaccine revealed it to be promising and well tolerated. The vaccine was shown to produce substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States.